Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors-Reference-Cited by-同舟云学术

Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors

Published:2015-04-10 Issue:8 Volume:58 Page:3548-3571
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Haffner Curt D.¹,Becherer J. David¹,Boros Eric E.¹,Cadilla Rodolfo¹,Carpenter Tiffany¹,Cowan David¹,Deaton David N.¹,Guo Yu¹,Harrington Wallace¹,Henke Brad R.¹,Jeune Michael R.¹,Kaldor Istvan¹,Milliken Naphtali¹,Petrov Kim G.¹,Preugschat Frank¹,Schulte Christie¹,Shearer Barry G.¹,Shearer Todd¹,Smalley Terrence L.¹,Stewart Eugene L.¹,Stuart J. Darren¹,Ulrich John C.¹

Affiliation:

1. Research and Development, GlaxoSmithKline, 5 Moore Drive, P.O. Box 13398, Research Triangle Park, North Carolina 27709, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm502009h

Reference35 articles.

1. NAD+metabolism: A therapeutic target for age-related metabolic disease

2. The Secret Life of NAD+: An Old Metabolite Controlling New Metabolic Signaling Pathways

3. Emerging Roles of NAD + and Its Metabolites in Cell SignalingA report on the NAD2008 symposium, Hamburg, Germany, 14 to 17 September 2008.